V-set and immunoglobulin domain-containing protein 4 (VSIG4) Antibody
299€ (50 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
V-set and immunoglobulin domain-containing protein 4 (VSIG4) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx402457
tested applications
ELISA
Description
V-set and immunoglobulin domain-containing protein 4 (VSIG4) Antibody is a Recombinant Human Monoclonal antibody for the detection of Human VSIG4.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | V-set and immunoglobulin domain-containing protein 4 (VSIG4) |
| Host | Human |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG1 |
| Expression | Recombinant |
| Purification | Purified by affinity chromatography. |
| Size 1 | 50 µl |
| Size 2 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q9Y279 |
| Alias | CRIg,Z39IG,Protein Z39Ig |
| Background | Antibody anti-VSIG4 |
| Status | RUO |
Descripción
V-set and immunoglobulin domain containing 4 (VSIG4) is a complement receptor and immune checkpoint protein that primarily functions as an inhibitory molecule in macrophages and antigen-presenting cells. As a negative regulator of T-cell activation, VSIG4 suppresses immune responses by binding to complement components, thereby reducing inflammation and preventing tissue damage in autoimmune and inflammatory conditions. Its immune-inhibitory properties make VSIG4 a potential target for immune modulation therapies, particularly in autoimmune diseases and cancer immunotherapy. In the tumor microenvironment, VSIG4 expression on macrophages is associated with immune evasion, as it inhibits T-cell-mediated anti-tumor responses. Elevated VSIG4 levels have been linked to poor prognosis in several cancers, including hepatocellular carcinoma and melanoma. Beyond its role in immunity, VSIG4 is implicated in metabolic processes, as it interacts with lipid metabolism pathways in macrophages, influencing foam cell formation in atherosclerosis. Therapeutic strategies targeting VSIG4 are being explored to enhance anti-tumor immunity or regulate excessive inflammation, highlighting its significance as a multifunctional immune regulatory molecule.
Related Products
Recombinant Mouse VSIG4
Ver Producto
Recombinant Human VSIG4
Ver Producto